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Spiro Heterocycles
An Enantio- and Diastereoselective Mannich/Pictet–Spengler
Sequence To Form Spiro[piperidine-pyridoindoles] and
Application to Library Synthesis
Alejandra Riesco-Domínguez,[a] Nick van der Zwaluw,[a] Daniel Blanco-Ania,[a] and
Floris P. J. T. Rutjes*[a]
Abstract: A new tandem strategy based on a Mannich/Pictet–
Spengler sequence has been developed and applied to the syn-
thesis of a new small library (14 examples) of privileged com-
pounds based on the spiro[piperidine-pyridoindole] core. The
sequence proceeds by a diastereoselective Pictet–Spengler cy-
Introduction
Spirocyclic compounds have been increasingly exploited as
lead compounds in the early phases of drug discovery due to
their unique properties, such as intrinsic three-dimensionality,
conformational restriction enhancing binding to a target and
structural patentability.[1] Over the past few years, various ex-
amples of natural compounds and synthetic drugs containing
spiro-fused heterocycles have been discovered to possess rele-
vant biological activities (Figure 1).[2] In particular, nitrogen-con-
taining spiro heterocycles have been identified as playing key
roles in biological and pharmaceutical processes,[3] rendering
this framework an attractive building block for further research.
Examples include iboluteine, an iboga-type indole alkaloid iso-
lated from the Apocynaceae family, fluspirilene, an antipsy-
chotic drug used for the treatment of schizophrenia, and fen-
spiride hydrochloride, an antitussive drug.
Figure 1. Natural and synthetic active compounds containing the spiro-piperi-
dine moiety.
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clization after condensation of several tryptamine derivatives
with three novel piperidin-4-ones containing the fluorinated
substituents F, CF3 and SF5. The piperidin-4-ones were synthe-
sized from readily available starting materials by an enantio-
selective multi-component organocatalytic Mannich reaction.
In this regard, substituents at the 2- and 6-positions of the
piperidine ring could be vital to modulate biological activity.[4]
Furthermore, it is well documented that the presence of fluor-
ine atoms can greatly enhance the drug-likeness of small mol-
ecules. As a result of properties such as electronegativity, atom
size and lipophilicity, the introduction of fluorine into small
molecules can effectively alter their biological activity and bio-
availability in comparison with their non-fluorinated counter-
parts.[5,6]
Inspired by previous piperidinone syntheses by our group,[7]
and in conjunction with current work on spirocyclic compound
libraries within the framework of the European Lead Factory,[8]
we herewith report an enantio- and diastereoselective reaction
sequence for the synthesis of spiro[2,6-diarylpiperidine-
pyridoindole] structures 7 and their utilization in the synthesis
of a focused compound library also containing a variety of
fluorine functionalities.
Results and Discussion
From a retrosynthetic point of view, the spiro[piperidine-
pyridoindole] core of compounds 7 can be generated from pip-
eridin-4-one 4 and substituted indole derivatives through a
diastereoselective Pictet–Spengler reaction (Scheme 1). The en-
antiopure piperidin-4-one 4 can itself be diastereoselectively
obtained from -amino ketone 3 by an intramolecular organo-
catalysed Mannich reaction. Lastly, amino ketone 3 should be
accessible through an enantioselective organocatalysed three-
component Mannich reaction with commercially available p-an-
isidine, 3,4-dimethoxybenzaldehyde and acetone.
The forward synthesis commenced with the preparation of
protected -amino ketone 1, as previously reported by our
group.[7] Compound 1 was obtained in 61 % yield and >99 %
ee through a multi-component L-proline-catalysed Mannich re-
action.[7,9] We selected compound 1 for the synthesis of this
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Scheme 1. Retrosynthesis of the spiro[piperidine-4,1′-pyrido[3,4-b]indole]
framework.
library due to the high relevance of the 3,4-dimethoxyphenyl
group in nature and active drugs.[10] From compound 1, two
possible synthetic routes for the synthesis of 2,6-disubstituted
piperidin-4-ones were envisioned (Scheme 2). Early efforts were
focused on the synthesis of p-methoxyphenyl (PMP) protected
piperidinones 2 in a one-pot procedure by a Mannich cycliza-
tion.
Scheme 2. Strategy for the synthesis of piperidin-4-one.
This approach involved the synthesis of the scaffold, which
proved a challenge owing to the high level of steric hindrance
arising from the three contiguous substituents.[11] In our efforts
to synthesize product 2, protected amine 1 was treated with
several aldehydes in the presence of various catalysts and under
a range of temperatures (see the Supporting Information). Un-
fortunately, none of these conditions led to the desired N-pro-
tected piperidin-4-one 2. Owing to these difficulties, we then
chose to synthesize the unprotected scaffold 4 with reduced
steric hindrance (Scheme 2). To this end, the N-PMP amine 1
was deprotected by employing H5IO6 under acidic conditions
to afford the corresponding product 3 in 46 % yield.[12] Subse-
quently, the free amino ketone 3 was treated with triethylamine
and 4-fluorobenzaldehyde to afford imine 5 (R = F). 1H NMR
analysis of the reaction mixture showed not only imine forma-
tion, but also the presence of a side-product, which could not
be characterized, and the cyclized product 4A. Several reaction
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conditions were investigated to achieve the full conversion of
imine 5 into the desired product 4A (Table 1). The conditions
previously reported by us[7] for these types of cyclizations were
unsuccessful (Table 1, Entry 4). After further investigation, we
found that full conversion to the cyclized product 4A could be
achieved when using L-proline as the catalyst (Table 1, Entry 6).
Table 1. Reaction conditions employed to optimize the synthesis of 4A.
Entry Reagent (equiv.) Solvent T [°C] Ratio 5/4A
1 Et3N (1) Et3N/1,2-DCE[a] 21–60 3.3:1
2 KOtBu (0.2) THF 21–70 2:1
3 Et3N (0.5) 1,2-DCE[a] 40 3.3:1
4 CSA (1.2) 1,2-DCE[a] 60 1.7:1
5 TFA (1.2) CH2Cl2 21 0.3:1
6 L-proline (0.2) MeCN 21 0:1
[a] 1,2-DCE = 1,2-dichloroethane.
In addition, 1H NMR analysis of the reaction mixtures showed
the existence of a slow equilibrium between imine 5 and cy-
clized product 4A under certain conditions, which led to differ-
ent ratios of products depending on the temperature. In this
manner, we observed that at low temperatures the formation
of 4A was favoured, whereas at room temperature imines 5
and 6 were the major compounds in the reaction mixture. The
presence of 5 and 6, 4-fluorobenzaldehyde and 3,4-dimethoxy-
benzaldehyde confirmed the existence of an equilibrium be-
tween compounds 4A, 5 and 6 (Scheme 3).
Scheme 3. Equilibria between 4a and imines 5 and 6.
Following the optimization of the two-step synthesis of 4A,
a one-pot procedure for the preparation of the cyclized product
directly from 3 was investigated. Thus, amine hydrochloride 3
was treated with Et3N and anhydrous Na2SO4 in the presence
of catalytic amounts of L-proline to afford the cyclized product
4A in 75 % yield. In the same way, two additional cis-2,6-diaryl-
piperidin-4-ones, 4B and 4C containing CF3 and SF5 groups,
were synthesized in yields of 38 and 28 %, respectively
(Scheme 2).[13] The mechanism for this diastereoselective cycli-
zation by an intramolecular Mannich reaction is depicted in
Scheme 4. First, the iminium ion species formed by the reaction
of amine 3 and the corresponding aldehyde adopts the lowest-
energy chair-like conformation in which the two hydrogen
atoms are in pseudo-axial positions. Then the enamine, formed
by L-proline and the ketone, attacks the iminium ion to form
Scheme 4. Mechanism for the diastereoselective cyclization reaction.
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the final piperidin-4-one with a cis configuration with the two
bulky aryl groups in equatorial positions. The cis stereochemis-
try of the products was confirmed by NOESY studies.
With the core scaffolds 4A–C in hand, we focused on the
development of a new library of spiro compounds based on
the derivatization of the ketone by the classic Pictet–Spengler
reaction.[14] Initially, 3-methoxy-, 3,4-dimethoxy- and 3-fluoro-
phenethylamine were selected as test substrates (Scheme 5).[15]
Scheme 5. Reactions of the piperidin-4-ones 4A–C with 2-phenylethylamines.
Test reactions without catalyst failed to achieve full conver-
sion into the corresponding imines. However, after thorough
investigation (see the Supporting Information), the reactions in
the presence of Ti(OiPr)4 showed complete conversion. When
performing the subsequent Pictet–Spengler reaction using
both TFA and TfOH as promoters, however, no cyclized product
was observed in any of the reactions.
Based on these preliminary results, the more reactive trypt-
amine was chosen as the model starting substrate (Table 2).
The reactions of 4A–C with tryptamine were carried out in di-
chloromethane in the presence of 4 Å molecular sieves, which
smoothly afforded the imine intermediate. The addition of TFA
at 0 °C then led to the diastereoselective formation of com-
pounds 7Aa–Ca in moderate yields (Table 2, Method A).
Further screening of the reaction conditions (see Table S7 in
the Supporting Information) led us to conclude that optimal
conversion into the imine could be achieved by the reaction of
the selected amine with Ti(OiPr)4 (1.3 equiv.) in the presence of
Et3N (1.2 equiv., only for substrates delivered as the hydrochlor-
ide salt) in THF at room temperature. As previously stated, the
addition of TFA at 0 °C then successfully delivered the desired
Pictet–Spengler cyclization products. It is important to note that
in all cases initially a mixture of the piperidin-4-one and imine
was formed, and full conversion into the imine could not be
achieved. By using these conditions, compounds 7Ab–Cd were
synthesized in an average yield of 67 %. It is worth noting that
TfOH was used as the acid in the synthesis of compounds 7Ad–
Cd. In these instances, the use of TFA in different amounts (2.2,
4.0 and 7.0 equiv.) was not sufficient for the cyclization to take
place.[16] The resulting molecules, which contain three N–H
groups, were difficult to purify by standard silica gel column
chromatography. For this reason, the products were isolated
by inactivation of the silica with Et3N. Moreover, after column
chromatography, an additional washing step was performed
with NH4OH (25 % in water) to remove residual triethylammo-
nium salts.
To explain the diastereoselectivity we propose a rationale
that is in accordance with the known reactivity of cyclohexan-
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Table 2. Scope of the Pictet–Spengler cyclization reaction.
[a] Method A: reaction carried out in CH2Cl2 in the presence of molecular
sieves, followed by the addition of TFA. Method B: Ti(OiPr)4 (1.3 equiv.) in THF
followed by the addition of TFA or TfOH. [b] Yield given based on recovered
starting material (BORSM) for compounds 7Ab–Cd.
ones towards nucleophiles.[17] The cyclization presumably pro-
ceeds through a chair-like transition state in which the indole
ring exclusively attacks from the equatorial direction, which is
the least hindered side (Scheme 6). 2D NMR studies (NOESY)
confirmed the stereochemistry of products 7Aa–Cd.
To extend this library of compounds and to further expand
the scope of the synthetic strategy, we synthesized compound
12 from indole-2-carbaldehyde, and compound 13 by using a
smaller pyrrole-based heterocycle (Schemes 7 and 8). First, the
Pictet–Spengler precursors 9 and 11 were synthesized starting
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Scheme 6. Rationale for the diastereoselectivity of the Pictet–Spengler cycli-
zation reaction.
from the commercially available indole-2-carbaldehyde and
pyrrole-2-carbaldehyde by Henry reactions with nitrometh-
ane.[18] Next, the intermediate nitro alkene 8 was reduced by
using LiAlH4 in Et2O for the synthesis of 9, and nitro alkene 10
was reduced with a mixture of NaBH4/NiCl2 to give 11
(Scheme 7).[19]
Scheme 7. Henry reaction and subsequent reduction for the synthesis of
amines 9 and 11.
Finally, precursors 9 and 11 were subjected to the previously
optimized conditions in the presence of piperidin-4-one 4A to
afford the corresponding Pictet–Spengler products 12 and 13
in 52 % yield with complete diastereoselectivity in both cases
(Scheme 8).
Scheme 8. Synthesis of spiro compounds 12 and 13.
Conclusions
An enantio- and diastereoselective route for the synthesis of a
new class of spirocyclic piperidine structures by means of a
Mannich and Pictet–Spengler reaction sequence has been de-
veloped. Three new cis-2,6-disubstituted piperidin-4-one ana-
logues containing fluorine functionalities were synthesized and
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incorporated into the synthetic route. Finally, this methodology
has been applied to the synthesis of a small library of com-
pounds consisting of a total of 14 examples, all as single stereo-
isomers. Currently, the biological properties of these com-
pounds are being evaluated in various assays.
Experimental Section
General Information: Full experimental details for the preparation
of the compounds described herein, as well as details related to
computational and mechanistic experiments, are provided in the
Supporting Information. Reagents were obtained from commercial
suppliers and used without purification. Standard syringe tech-
niques were applied for the transfer of dry solvents and air- or
moisture-sensitive reagents. TLC detection was performed with UV
light and/or by charring at around 150 °C after dipping into a
solution of either 2 % anisaldehyde in ethanol/H2SO4,
(NH4)6Mo7O24·4H2O (25 g/L), or ninhydrin. Column or flash chroma-
tography was carried out by using ACROS silica gel (0.035–
0.070 mm, 60 Å pore diameter). IR spectra were recorded with an
IR-ATR Bruker TENSOR 27 spectrometer. High-resolution mass spec-
tra were recorded with a JEOL AccuTOF (ESI) or a MAT900 (EI, CI
and ESI) spectrometer. Optical rotations were determined with a
Perkin–Elmer 241 polarimeter. NMR spectra were recorded at 298 K
with a Varian Inova 400 (400 MHz), a Bruker Avance III 400 MHz, or
a Bruker Avance III 500 MHz spectrometer in the solvent indicated.
Chemical shifts are given in parts per million (ppm) with respect to
tetramethylsilane (δ = 0.00 ppm) or CHD2OD (δ = 3.31 ppm) as
internal standard for 1H NMR and CDCl3 (δ = 77.16 ppm) or CD3OD
(δ = 49.00 ppm) as internal standard for 13C NMR. Coupling con-
stants are reported as J values in Hz. 1H NMR data are reported as
follows: chemical shift (ppm), multiplicity (s = singlet, d = doublet,
dd = doublet of doublets, dt = doublet of triplets, ddd = doublet of
doublet of doublets, t = triplet, m = multiplet, br. = broad), coupling
constants (Hz) and integration. The compounds were fully charac-
terized by 1H and 13C NMR spectra and 2D gDQCOSY, gHSQC,
gHMBC and NOESY spectra.
(4S)-4-(3,4-Dimethoxyphenyl)-4-[(4-methoxyphenyl)amino]-
butan-2-one (1): 3,4-Dimethoxybenzaldehyde (10.5 g, 63.2 mmol),
4-anisidine (7.78 g, 63.2 mmol) and L-proline (1.5 g, 12.64 mmol)
were added to a mixture of DMSO (45 mL) and acetone (180 mL).
The resulting reaction mixture was stirred for 23 h. The reaction
was then quenched with potassium phosphate buffer (0.5 M, pH 7,
100 mL). Subsequently, potassium phosphate buffer (0.5 M, pH 7, a
total of 150 mL) was added in portions. The reaction mixture was
cooled to 0 °C, and the product started to precipitate. After stirring
for 20 min, the suspension was filtered and the residue was washed
with water (0 °C, 50 mL). The product was dried in vacuo. The prod-
uct was obtained as an off-white powder (19 g) and recrystallized
from EtOAc to give white crystals (12.7 g, 38.5 mmol). Yield: 61 %.
HPLC: ee >99 %, Chiralpak AD-H (250 × 4.6 mm), flow: 1.0 mL/min,
heptane/propan-2-ol (80:20), retention time: 1: 18.7 min, ent-1:
15.7 min. M.p. 147–151 °C. [α]D20 = +2.4 (c = 0.41, CHCl3). 1H NMR
(400 MHz, CDCl3): δ = 6.91–6.86 (m, 2 H), 6.83–6.77 (m, 1 H), 6.72–
6.66 (m, 2 H), 6.55–6.48 (m, 2 H), 4.69 (t, J = 6.5 Hz, 1 H), 3.84 (s, 6
H), 3.69 (s, 3 H), 2.88 (d, J = 6.5 Hz, 2 H), 2.10 (s, 3 H) ppm. 13C NMR
(101 MHz, CDCl3): δ = 207.5, 152.5, 149.3, 148.2, 141.1, 135.5, 118.3,
115.5, 114.8, 111.3, 109.6, 56.0, 55.9, 55.7, 55.3, 51.5, 30.9 ppm. FTIR:
ν˜ = 3385, 1708, 1510, 1253, 1235, 1139, 1027, 821 cm–1. HRMS (ESI):
calcd. for C38H46N2O8Na [M + Na]+ 352.15248; found 352.15248.
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(4S)-4-Amino-4-(3,4-dimethoxyphenyl)butan-2-one Hydro-
chloride (3): Aqueous H2SO4 (1 M, 12.1 mL, 12.1 mmol) and H5IO6
(2.87 g, 12.6 mmol) were added to a solution of (4S)-4-(3,4-di-
methoxyphenyl)-4-(4-methoxyphenylamino)butan-2-one (1; 4 g,
12.1 mmol) in MeCN/H2O (1:1, 120 mL). The mixture was stirred at
room temperature for 1.5 h, washed with CH2Cl2 (3 × 60 mL), and
the resulting aqueous phase was diluted with CH2Cl2 (60 mL). The
pH of the aqueous layer was brought to 9 by the addition of 5 M
aqueous KOH under vigorous stirring. The layers were separated,
and the aqueous layer was extracted with CH2Cl2 (3 × 60 mL). The
combined organic layers were dried with Na2SO4, and HCl/EtOAc
(9.5 mL) was added. The resulting mixture was concentrated until
the product precipitated. The product was isolated by filtration and
dried in vacuo to afford 3 (1.44 g, 5.54 mmol) as a pale-yellow solid.
Yield: 46 %. 1H NMR (400 MHz, CD3OD): δ = 7.03 (d, J = 1.8 Hz, 1
H), 7.00–6.96 (m, 2 H), 4.64 (t, J = 6.8 Hz, 1 H), 3.87 (s, 3 H), 3.84 (s,
3 H), 3.20 (d, J = 6.8 Hz, 2 H), 2.20 (s, 3 H) ppm. 13C NMR (101 MHz,
CD3OD): δ = 207.5, 151.2, 150.9, 130.3, 121.1, 113.1, 112.1, 56.7, 56.5,
52.2, 47.6, 30.1 ppm. FTIR: ν˜ = 3395, 2936, 1709, 1515, 1264, 1143,
1018 cm–1. HRMS (ESI): calcd. for [C12H18NO3 + H]+ 224.12867; found
224.13151 (|Δ| = 12.69 ppm).
(3S)-4-(3,4-Dimethoxyphenyl)-4-[(E)-(4-fluorobenzylidene)-
amino]butan-2-one (5): Triethylamine (0.44 mL, 3.18 mmol) and 4-
fluorobenzaldehyde (0.34 mL, 3.18 mmol) were added to a solution
of 3 (1.65 g, 6.36 mmol) in dry 1,2-dichloroethane (115 mL). The
mixture was concentrated in vacuo. Dry 1,2-dichloroethane
(110 mL) was added to the residue, and the mixture was concen-
trated again in vacuo. Dry 1,2-dichloroethane (110 mL) and triethyl-
amine (0.44 mL, 3.18 mmol) were added to the resulting mixture,
which was concentrated in vacuo. The mixture was dissolved in dry
1,2-dichloroethane (113 mL), and tr iethylamine (0.44 mL,
3.18 mmol) and 4-fluorobenzaldehyde (0.03 mL, 0.32 mmol) were
added. The resulting mixture was concentrated in vacuo to afford
the crude imine. 1H NMR (400 MHz, CD3OD): δ = 8.33 (s, 1 H), 7.77–
7.70 (m, 2 H), 7.10–7.04 (m, 2 H), 6.98–6.93 (m, 2 H), 6.85–6.82 (m,
1 H), 4.85 (dd, J = 8.9, 4.2 Hz, 1 H), 3.90 (s, 3 H), 3.86 (s, 3 H), 3.21
(dd, J = 16.3, 8.9 Hz, 1 H), 2.89 (dd, J = 16.3, 4.2 Hz, 1 H), 2.11 (s, 3
H) ppm.
General Procedure for the Synthesis of Compounds 4A–C: A
mixture of 3 (1.00 equiv.), triethylamine (1.00 equiv.), the corre-
sponding aldehyde (1.00 equiv.), L-proline (0.20 equiv.) and anhy-
drous Na2SO4 (0.28 equiv.) in EtOH was stirred at room temperature
under an inert gas for 3–4 h. Then the reaction was quenched with
NH4Cl (75 mL), and the aqueous layer was extracted with EtOAc
(3 × 200 mL). The organic layers were combined and extracted with
a solution 0.1 M HCl (3 × 200 mL). The combined aqueous layers
were washed with EtOAc and neutralized with 1.0 M aqueous so-
dium hydroxide to pH 7–8. The aqueous layer was extracted with
EtOAc (3 × 200 mL), saturated brine solution was added, and the
organic layers were dried with anhydrous Na2SO4, filtered and con-
centrated under reduced pressure to afford compounds 4A–C.
(2S,6R)-2-(3,4-Dimethoxyphenyl)-6-(4-fluorophenyl)piperidin-4-
one (4A): According to the general procedure, the reaction of
amino ketone hydrochloride 3 (2.5 g, 9.63 mmol) and 4-fluoro-
benzaldehyde afforded 4A (2.4 g, 7.28 mmol) as an orange solid.
Yield: 75 %. RF = 0.50 (heptane/EtOAc, 1:1). 1H NMR (400 MHz,
CDCl3): δ = 7.48–7.41 (m, 2 H), 7.08–7.02 (m, 2 H), 7.02–6.96 (m, 2
H), 6.85 (d, J = 8.1 Hz, 1 H), 4.05 (dd, J = 10.2, 4.5 Hz, 1 H), 4.01 (dd,
J = 10.9, 3.7 Hz, 1 H), 3.92 (s, 3 H), 3.88 (s, 3 H), 2.66–2.50 (m, 4
H) ppm. 13C NMR (101 MHz, CDCl3): δ = 208.1, 162.4 (d, J =
246.2 Hz), 149.3, 148.8, 138.6 (d, J = 3.1 Hz), 135.4, 128.3 (d, J =
8.1 Hz, 2 ×), 118.8, 115.7 (d, J = 21.3 Hz, 2 ×), 111.3, 109.7, 61.1,
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60.6, 56.1, 56.1, 50.7, 50.6 ppm. FTIR: ν˜ = 3305, 1710, 1509, 1264,
1232 cm–1. HRMS (ESI): calcd. for [C19H20FNO3 + H]+ 330.15055;
found 330.15190 (|Δ| = 4.11 ppm).
(2S,6R)-2-(3,4-Dimethoxyphenyl)-6-[4-(trifluoromethyl)phen-
yl]piperidin-4-one (4B): According to the general procedure, the
reaction of amino ketone hydrochloride 3 (2.5 g, 9.63 mmol) and
4-(trifluoromethyl)benzaldehyde afforded 4B (1.4 g, 3.70 mmol) as
an orange solid. Yield: 38 %. RF = 0.60 (heptane/EtOAc, 1:1). 1H NMR
(400 MHz, CDCl3): δ = 7.66–7.56 (m, 4 H), 7.03–6.97 (m, 2 H), 6.85
(d, J = 8.1 Hz, 1 H), 4.14 (dd, J = 8.6, 7.0 Hz, 1 H), 4.03 (dd, J = 11.0,
3.6 Hz, 1 H), 3.92 (s, 3 H), 3.88 (s, 3 H), 2.68–2.53 (m, 4 H) ppm. 13C
NMR (101 MHz, CDCl3): δ = 207.5, 149.4, 148.9, 146.7 (q, J = 1.2 Hz),
135.2, 130.3 (q, J = 32.5 Hz), 127.1 (2 ×), 125.9 (q, J = 3.7 Hz, 2 ×),
122.7 (CF3, indirect observation), 118.8, 111.3, 109.7, 61.1, 60.8, 56.1,
50.6, 50.3 ppm. HRMS (ESI): calcd. for [C20H21F3NO3 + H]+ 380.14735;
found 380.14778 (|Δ| = 1.13 ppm).
(2S,6R)-2-(3,4-Dimethoxyphenyl)-6-[4-(pentafluoro-λ6-sulfanyl)-
phenyl]piperidin-4-one (4C): According to the general procedure,
the reaction of amino ketone hydrochloride 3 (2.2 g, 8.61 mmol)
and 4-(pentafluorosulfanyl)benzaldehyde afforded 4C (1.07 g,
2.45 mmol) as a yellow solid. Yield: 28 %. RF = 0.60 (heptane/EtOAc,
1:1). 1H NMR (400 MHz, CDCl3): δ = 7.79–7.74 (m, 2 H), 7.61–7.56
(m, 2 H), 7.03–6.96 (m, 2 H), 6.86 (d, J = 7.9 Hz, 1 H), 4.17–4.12 (dd,
J = 8.3, 6.5 Hz, 1 H), 4.04 (dd, J = 11.0, 3.3 Hz, 1 H), 3.92 (s, 3 H),
3.88 (s, 3 H), 2.69–2.50 (m, 4 H) ppm. 13C NMR (101 MHz, CDCl3):
δ = 207.2, 153.7 (indirect observation), 149.4, 148.9, 146.6–146.5
(m), 135.1, 127.1 (2 ×), 126.7–126.5 (2 ×), 118.8, 111.3, 109.7, 61.1,
60.5, 56.1, 50.6, 50.2 ppm. FTIR: ν˜ = 1714, 1517, 829 cm–1. HRMS
(ESI): calcd. for [C19H21F5NO3S + H]+ 438.11623; found 438.11611
(|Δ| = 0.27 ppm).
General Procedure for the Synthesis of Compounds 7Aa–Ca: A
mixture of piperidin-4-one 4A–C (1.00 equiv.) and tryptamine
(1.00 equiv. for the synthesis of 7Aa and 7Ca and 1.60 equiv. for
the synthesis of 7Ba) dissolved in CH2Cl2 in the presence of molec-
ular sieves was stirred at 21 °C under an inert gas for the time
indicated in each case. Then the solution was cooled to 0 °C, TFA
(2.2 equiv.) was added and the reaction mixture was warmed to
21 °C and stirred for the time indicated in each case. The reaction
was quenched with a saturated NaHCO3 solution, and the aqueous
layer was extracted with CH2Cl2 (3 ×). The combined organic layers
were washed with brine, dried with Na2SO4, filtered and concen-
trated in vacuo.
(2S,4S,6R)-2-(3,4-Dimethoxyphenyl)-6-(4-fluorophenyl)-
2′,3′,4′,9′-tetrahydrospiro[piperidine-4,1′-pyrido[3,4-b]indole]
(7Aa): According to the general procedure, the reaction mixture of
piperidin-4-one 4A (51.5 mg, 0.16 mmol) was stirred in CH2Cl2
(2.5 mL) overnight to form the imine. TFA (27 μL, 0.34 mmol) in
CH2Cl2 (0.14 mL) was added, and the mixture was stirred for 48 h.
The crude mixture was purified by column chromatography [hept-
ane/EtOAc (4:1) → EtOAc] and ion-exchange column chromatogra-
phy (ISOLUTE SCX-2) to afford compound 7Aa (38.5 mg, 0.08 mmol)
as a yellow solid. Yield: 52 %. RF = 0.43 (EtOAc). 1H NMR (500 MHz,
CDCl3): δ = 7.86 (br. s, 1 H), 7.49–7.44 (m, 3 H), 7.29 (d, J = 8.0 Hz,
1 H), 7.13 (ddd, J = 8.1, 7.1, 1.3 Hz, 1 H), 7.10–7.06 (m, 1 H), 7.06–
6.98 (m, 4 H), 6.83 (d, J = 8.2 Hz, 1 H), 4.50–4.43 (m, 1 H), 4.40 (dd,
J = 10.9, 3.1 Hz, 1 H), 3.92 (s, 3 H), 3.86 (s, 3 H), 3.26 (t, J = 5.7 Hz,
2 H), 2.75 (t, J = 5.7 Hz, 2 H), 2.08–1.93 (m, 4 H) ppm. 13C NMR
(126 MHz, CDCl3): δ = 162.1 (d, J = 244.7 Hz), 149.1, 148.4, 140.5,
139.4, 137.3, 135.6, 128.4 (d, J = 7.9 Hz, 2 ×), 127.6, 121.9, 119.5,
119.0, 118.3, 115.4 (d, J = 21.1 Hz, 2 ×), 111.3, 110.9, 110.2, 108.9,
56.6, 56.3, 56.1, 56.1, 53.3, 45.1, 45.1, 39.4, 23.3 ppm. FTIR: ν˜ = 3364,
2933, 2835, 1603, 1507, 1223, 1136, 1025, 804 cm–1. HRMS (ESI):
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calcd. for [C29H30FN3O2 + H]+ 472.23985; found 472.24003 (|Δ| =
0.4 ppm).
(2S,4S,6R)-2-(3,4-Dimethoxyphenyl)-6-[4-(trifluoromethyl)-
phenyl]-2′,3′,4′,9′-tetrahydrospiro[piperidine-4,1′-pyrido[3,4-b]-
indole] (7Ba): According to the general procedure, the reaction
mixture of piperidin-4-one 4B (100 mg, 0.26 mmol) was stirred, in
the presence of 4 Å molecular sieves, in CH2Cl2 (5 mL) for 5 h to
form the imine. TFA (44 μL, 0.57 mmol) in CH2Cl2 (0.25 mL) was
added, and the mixture was stirred for 24 h. The crude product
was purified by two column chromatographic procedures [heptane/
EtOAc (3:1) → EtOAc/MeOH (10:1) and heptane/EtOAc (2:3) →
EtOAc/MeOH (10:1)] to afford compound 7Ba (56.6 mg, 0.11 mmol).
Yield: 41 %. RF = 0.22 (heptane/EtOAc, 2:3). 1H NMR (400 MHz,
CDCl3): δ = 7.84 (br. s, 1 H), 7.67–7.55 (m, 4 H), 7.47 (d, J = 7.7 Hz,
1 H), 7.27 (dt, J = 8.0, 0.9 Hz, 1 H), 7.13 (ddd, J = 8.1, 7.1, 1.3 Hz, 1
H), 7.10–7.01 (m, 3 H), 6.84 (d, J = 8.1 Hz, 1 H), 4.54 (dd, J = 10.5,
3.5 Hz, 1 H), 4.42 (dd, J = 10.4, 3.4 Hz, 1 H), 3.92 (s, 3 H), 3.87 (s, 3
H), 3.34–3.20 (m, 2 H), 2.75 (t, J = 5.7 Hz, 2 H), 2.08–1.90 (m, 4 H)
ppm. 13C NMR (101 MHz, CDCl3): δ = 149.1, 149.0 (q, J = 1.0 Hz),
148.4, 139.2, 137.3, 135.6, 129.6 (q, J = 32.3 Hz), 127.5, 127.2 (2×),
125.6 (q, J = 3.7 Hz, 2 ×), 124.3 (q, J = 272.2 Hz, CF3), 122.0, 119.6,
118.9, 118.4, 111.3, 110.9, 110.1, 109.0, 56.6, 56.4, 56.1 (2 ×), 53.2,
45.2, 45.0, 39.4, 23.3 ppm. FTIR: ν˜ = 3367, 2931, 2838, 1618, 1516,
1261, 1118, 1017, 806 cm–1. HRMS (ESI): calcd. for [C30H30F3N3O2 +
H]+ 522.23708; found 522.23684 (|Δ| = 0.5 ppm).
(2S,4S,6R)-2-(3,4-Dimethoxyphenyl)-6-[4-(pentafluoro-λ6-
sulfanyl)phenyl]-2′,3′,4′,9′-tetrahydrospiro[piperidine-4,1′-pyr-
ido[3,4-b]indole] (7Ca): According to the general procedure, the
reaction mixture of piperidin-4-one 4C (40 mg, 0.09 mmol) was
stirred, in the presence of 4 Å molecular sieves, in CH2Cl2 (1.5 mL)
for 5 h to form the imine. TFA (20 μL, 0.20 mmol) was added, and
the mixture was stirred overnight. The crude product was purified
by column chromatography [heptane/EtOAc (4:1) → EtOAc] to af-
ford compound 7Ca (24.4 mg, 0.042 mmol). Yield: 47 %. RF = 0.34
(heptane/EtOAc, 2:3). 1H NMR (400 MHz, CDCl3): δ = 7.89 (s, 1 H),
7.75–7.69 (m, 2 H), 7.62–7.57 (m, 2 H), 7.48 (d, J = 7.7 Hz, 1 H), 7.27
(d, J = 7.4 Hz, 1 H), 7.14 (t, J = 7.5 Hz, 1 H), 7.11–7.01 (m, 3 H), 6.85
(d, J = 8.1 Hz, 1 H), 4.55 (dd, J = 10.3, 2.9 Hz, 1 H), 4.43 (dd, J =
10.6, 2.7 Hz, 1 H), 3.92 (s, 3 H), 3.87 (s, 3 H), 3.37–3.17 (m, 2 H), 2.76
(t, J = 5.5 Hz, 2 H), 2.12–1.91 (m, 4 H), 1.86 (br. s, 1 H) ppm. 13C
NMR (101 MHz, CDCl3): δ = 152.9 (quint, J = 17.1 Hz), 149.1, 148.8,
148.4, 139.1, 137.1, 135.6, 127.5, 127.1 (2 ×), 126.3 (quint, J = 4.6 Hz,
2 ×), 122.0, 119.5, 118.9, 118.4, 111.3, 110.9, 110.1, 109.0, 56.3 (2 ×),
56.1, 56.1, 53.2, 45.1, 44.8, 39.4, 23.2 ppm. FTIR: ν˜ = 3373, 2934,
2838, 1592, 1515, 1232, 1138, 1027, 840 cm–1. HRMS (ESI): calcd. for
[C29H31F5N3O2S + H]+ 580.20571; found 580.20471 (|Δ| = 1.73 ppm).
General Procedure for the Synthesis of Compounds 7Ab–Cb: A
solution of Ti(OiPr)4 (1.30 equiv.) in dry THF (0.5 mL) was added to
a mixture of piperidin-4-one 4A–C (1.00 equiv.) and 6-methoxytryp-
tamine (1.20 equiv.) in dry THF (2 mL) at 21 °C under argon. After
6 h, TFA (2.20 equiv.) dissolved in dry THF (0.5 mL) was added at
0 °C, and the reaction mixture was warmed to 21 °C and stirred for
19–24 h. The reaction was quenched with a saturated NaHCO3 solu-
tion and the mixture diluted with EtOAc. The layers were separated,
and the aqueous phase was extracted with EtOAc (3 ×). The com-
bined organic layers were washed with brine, dried with Na2SO4,
filtered and concentrated in vacuo. The crude product was purified
by column chromatography [heptane/EtOAc (2:1) → EtOAc/MeOH
(10:1)]. The dried product was dissolved in CH2Cl2 (5 mL) and
washed with aqueous NH4OH (5 mL). The aqueous phase was ex-
tracted with CH2Cl2 (3 × 5 mL), and the combined organic layers
were washed with brine, dried with Na2SO4, filtered and dried in
vacuo to afford compounds 7Ab–Cb.
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(2S,4S,6R)-2-(3,4-Dimethoxyphenyl)-6-(4-fluorophenyl)-7′-meth-
oxy-2′,3′,4′,9′-tetrahydrospiro[piperidine-4,1′-pyrido[3,4-b]-
indole] (7Ab): According to the general procedure, the reaction of
piperidin-4-one 4A (50 mg, 0.152 mmol) afforded 7Ab (41.5 mg,
0.083 mmol). Yield (BORSM): 74 %. RF = 0.30 (heptane/EtOAc/Et3N,
4:4:1). 1H NMR (400 MHz, CDCl3): δ = 7.79 (br. s, 1 H), 7.48–7.44 (m,
2 H), 7.33 (d, J = 8.6 Hz, 1 H), 7.05 (d, J = 1.9 Hz, 1 H), 7.03–6.98 (m,
3 H), 6.82 (d, J = 8.3 Hz, 1 H), 6.80 (d, J = 2.2 Hz, 1 H), 6.74 (dd, J =
8.6, 2.2 Hz, 1 H), 4.44 (dd, J = 9.1, 4.9 Hz, 1 H), 4.39 (dd, J = 11.0,
2.9 Hz, 1 H), 3.91 (s, 3 H), 3.86 (s, 3 H), 3.81 (s, 3 H), 3.24 (t, J =
5.7 Hz, 2 H), 2.70 (t, J = 5.7 Hz, 2 H), 2.06–1.92 (m, 4 H), 1.72 (br. s,
2 H) ppm. 13C NMR (126 MHz, CDCl3): δ = 162.1 (d, J = 245.0 Hz),
156.4, 149.1, 148.3, 140.5, 138.2, 137.3, 136.4, 128.4 (d, J = 7.9 Hz,
2 ×), 122.0, 118.9, 118.8, 115.4 (d, J = 21.2 Hz, 2 ×), 111.2, 110.1,
108.9, 108.7, 95.1, 56.6, 56.3, 56.1 (2 ×), 55.9, 53.2, 45.1, 45.0, 39.4,
23.3 ppm. FTIR: ν˜ = 3366, 2931, 2835, 1628, 1507, 1223, 1153, 1025,
764 cm–1. HRMS (ESI): calcd. for [C30H32FN3O3 + H]+ 502.25093;
found 502.25059 (|Δ| = 0.7 ppm).
(2S,4S,6R)-2-(3,4-Dimethoxyphenyl)-7′-methoxy-6-[4-(trifluoro-
methyl)phenyl]-2′,3′,4′,9′-tetrahydrospiro[piperidine-4,1′-pyr-
ido[3,4-b]indole] (7Bb): According to the general procedure, the
reaction of piperidin-4-one 4B (50 mg, 0.132 mmol) afforded 7Bb
(56.0 mg, 0.102 mmol). Yield: 77 %. RF = 0.32 (heptane/EtOAc/Et3N,
4:4:1). 1H NMR (500 MHz, CDCl3): δ = 7.69 (br. s, 1 H), 7.64–7.55 (m,
4 H), 7.34 (d, J = 8.6 Hz, 1 H), 7.06–7.01 (m, 2 H), 6.84 (d, J = 8.2 Hz,
1 H), 6.80 (d, J = 2.2 Hz, 1 H), 6.75 (dd, J = 8.6, 2.2 Hz, 1 H), 4.53
(dd, J = 11.1, 2.3 Hz, 1 H), 4.41 (dd, J = 10.3, 3.5 Hz, 1 H), 3.92 (s, 3
H), 3.87 (s, 3 H), 3.81 (s, 3 H), 3.28–3.22 (m, 2 H), 2.71 (t, J = 5.6 Hz,
2 H), 2.05–1.89 (m, 4 H), 1.62 (br. s, 2 H) ppm. 13C NMR (101 MHz,
CDCl3): δ = 156.4, 149.1, 149.0, 148.4, 138.1, 137.3, 136.4, 129.6 (q,
J = 32.3 Hz), 127.2 (2 ×), 125.5 (q, J = 3.7 Hz, 2 ×), 124.3 (q, J =
272.0 Hz, CF3), 122.0, 118.9, 118.8, 111.3, 110.2, 108.8, 108.7, 95.2,
56.6, 56.4, 56.1 (2 ×), 55.9, 53.2, 45.1, 44.9, 39.4, 23.3 ppm. FTIR: ν˜ =
3369, 2926, 2835, 1619, 1515, 1260, 1097, 1066, 797 cm–1. HRMS
(ESI): calcd. for [C31H32F3N3O3 + H]+ 552.24737; found 552.24740
(|Δ| = 0.1 ppm).
(2S,4S,6R)-2-(3,4-Dimethoxyphenyl)-7′-methoxy-6-[4-(penta-
fluoro-λ6-sulfanyl)phenyl]-2′,3′,4′,9′-tetrahydrospiro[piper-
idine-4,1′-pyrido[3,4-b]indole] (7Cb): According to the general
procedure, the reaction of piperidin-4-one 4C (50 mg, 0.114 mmol)
afforded 7Cb (18.1 mg, 0.030 mmol). In this case, after applying the
general procedure, the crude product was purified by a second
column chromatography [heptane/EtOAc (2:1) → EtOAc/MeOH
(10:1)] and ion-exchange column chromatography (ISOLUTE SCX-2).
The dried product was dissolved again in CH2Cl2 (5 mL) and washed
with aqueous NH4OH (5 mL). The combined aqueous layers were
extracted with CH2Cl2 (3 × 5 mL), and the organic layers were
washed with brine, dried with Na2SO4, filtered and dried in vacuo.
Yield (BORSM): 56 %. RF = 0.28 (heptane/EtOAc/Et3N, 4:4:1). 1H NMR
(400 MHz, CDCl3): δ = 7.73–7.70 (m, 2 H), 7.68 (br. s, 1 H), 7.61–7.57
(m, 2 H), 7.34 (d, J = 8.6 Hz, 1 H), 7.04 (d, J = 2.0 Hz, 1 H), 7.02 (dd,
J = 8.2, 2.0 Hz, 1 H), 6.84 (d, J = 8.2 Hz, 1 H), 6.79 (d, J = 2.2 Hz, 1
H), 6.75 (dd, J = 8.6, 2.2 Hz, 1 H), 4.53 (dd, J = 11.1, 2.2 Hz, 1 H),
4.41 (dd, J = 10.4, 3.5 Hz, 1 H), 3.92 (s, 3 H), 3.87 (s, 3 H), 3.81 (s, 3
H), 3.28–3.21 (m, 2 H), 2.71 (t, J = 5.7 Hz, 2 H), 2.04–1.87 (m, 4 H),
1.62 (br. s, 2 H) ppm. 13C NMR (126 MHz, CDCl3): δ = 156.5, 152.9
(quint, J = 17.6 Hz), 149.1, 148.8, 148.5, 137.9, 137.1, 136.4, 127.1
(2 ×), 126.3 (quint, J = 4.4 Hz, 2 ×), 122.0, 118.9, 118.9, 111.3, 110.1,
108.9, 108.8, 95.2, 56.3 (2 ×), 56.1, 56.1, 55.9, 53.2, 45.1, 44.8, 39.4,
23.3 ppm. FTIR: ν˜ = 3371, 2938, 2837, 1629, 1516, 1262, 1154, 1027,
823, 729 cm–1. HRMS (ESI): calcd. for [C30H32F5N3O3S + H]+
610.21561; found 610.21628 (|Δ| = 1.1 ppm).
Full Paper
(2S,4S,6R)-2-(3,4-Dimethoxyphenyl)-6-(4-fluorophenyl)-
2′,3′,4′,9′-tetrahydrospiro[piperidine-4,1′-pyrido[3,4-b]indol]-6′-
ol (7Ac): Et3N (25 μL, 0.182 mmol) dissolved in dry THF (0.25 mL)
and Ti(OiPr)4 (58 μL, 0.197 mmol) dissolved in dry THF (0.25 mL)
were added to a mixture of 4A (50 mg, 0.152 mmol) and 5-hydroxy-
tryptamine hydrochloride (38.7 mg, 0.182 mmol) dissolved in dry
THF (0.5 mL). After 30 min, additional Et3N (25 μL, 0.182 mmol) and
THF (16.5 mL) were added. After 4.5 h, TFA (52 μL, 0.668 mmol)
dissolved in dry THF (0.5 mL) was added at 0 °C, and the reaction
mixture was warmed to 21 °C and stirred for 21 h. The reaction
was quenched with an aqueous saturated NaHCO3 solution and the
mixture diluted with EtOAc. The organic and aqueous phases were
separated, and the aqueous phase was extracted with EtOAc (4 ×).
The combined organic layers were washed with brine, dried with
Na2SO4, filtered and dried in vacuo. The crude product was dis-
solved in dry THF (2 mL), and 5-hydroxytryptamine hydrochloride
(15.5 mg, 0.073 mmol), Et3N (10 μL, 0.073 mmol) in dry THF (0.5 mL)
and Ti(OiPr)4 (23.2 μL, 0.079 mmol) were added. After 3 h, TFA
(10.4 μL, 0.134 mmol) was added at 0 °C, and the reaction mixture
was warmed to 21 °C and stirred for 20.5 h. The reaction was
quenched with an aqueous saturated NaHCO3 solution and diluted
with EtOAc. The organic and aqueous phases were separated, and
the aqueous phase was extracted with EtOAc (4 ×). The combined
organic layers were washed with brine, dried with Na2SO4, filtered
and dried in vacuo. The crude product was purified by column chro-
matography [EtOAc → EtOAc/MeOH (10:1)]. The dried product was
dissolved in CH2Cl2 (5 mL) and washed with aqueous NH4OH (2 ×
5 mL). The combined aqueous layers were extracted with CH2Cl2
(3 × 10 mL), and the combined organic layers were washed with
brine, dried with Na2SO4, filtered and dried in vacuo to afford 7Ac
(37.0 mg, 0.076 mmol) as a yellow solid. Yield (BORSM): 80 %. RF =
0.32 (EtOAc/Et3N, 8:1). 1H NMR (500 MHz, CDCl3): δ = 7.81 (br. s, 1
H), 7.45 (m, 2 H), 7.09 (d, J = 8.6 Hz, 1 H), 7.05 (d, J = 2.0 Hz, 1 H),
7.03–6.96 (m, 3 H), 6.84 (d, J = 2.4 Hz, 1 H), 6.81 (d, J = 8.2 Hz, 1 H),
6.67 (dd, J = 8.6, 2.4 Hz, 1 H), 4.44 (dd, J = 10.4, 3.6 Hz, 1 H), 4.39
(dd, J = 11.1, 2.6 Hz, 1 H), 3.87 (s, 3 H), 3.85 (s, 3 H), 3.22 (t, J =
5.7 Hz, 2 H), 2.63 (t, J = 5.7 Hz, 2 H), 2.10–1.93 (m, 4 H) ppm. 13C
NMR (101 MHz, CDCl3): δ = 162.1 (d, J = 245.2 Hz), 149.6, 149.1,
148.4, 140.6, 140.2 (d, J = 2.9 Hz), 137.1, 130.9, 128.5 (d, J = 7.9 Hz,
2 ×), 128.3, 119.0, 115.4 (d, J = 21.2 Hz, 2 ×), 111.5, 111.5, 111.3,
110.2, 108.4, 103.4, 56.7, 56.4, 56.1, 56.1, 53.4, 44.8 (2 ×), 39.3,
23.2 ppm. FTIR: ν˜ = 3367, 2931, 2838, 1591, 1515, 1261, 1118, 1016,
800 cm–1. HRMS (ESI): calcd. for [C29H30FN3O3 + H]+ 488.23454;
found 488.23494 (|Δ| = 0.8 ppm).
(2S,4S,6R)-2-(3,4-Dimethoxyphenyl)-6-[4-(trifluoromethyl)-
phenyl]-2′,3′,4′,9′-tetrahydrospiro[piperidine-4,1′-pyrido[3,4-b]-
indol]-6′-ol (7Bc): Et3N (22 μL, 0.158 mmol) dissolved in dry THF
(0.50 mL) and Ti(OiPr)4 (50 μL, 0.171 mmol) dissolved in dry THF
(0.50 mL) were added to a mixture of 4B (50 mg, 0.132 mmol) and
5-hydroxytryptamine hydrochloride (33.6 mg, 0.158 mmol) dis-
solved in dry THF (2 mL). After 7 h, TFA (22 μL, 0.290 mmol) dis-
solved in dry THF (0.5 mL) was added at 0 °C, and the reaction
mixture was warmed to 21 °C and stirred for 23 h. The reaction
was quenched with an aqueous saturated NaHCO3 solution and the
mixture diluted with EtOAc. The organic and aqueous phases were
separated, and the aqueous phase was extracted with EtOAc (4 h).
The combined organic layers were washed with brine, dried with
Na2SO4, filtered and dried in vacuo. The crude product was dis-
solved in dry THF (1.5 mL), and 5-hydroxytryptamine hydrochloride
(33.6 mg, 0.158 mmol), Et3N (22 μL, 0.158 mmol) in dry THF (0.5 mL)
and Ti(OiPr)4 (50 μL, 0.171 mmol) were added. After 7 h, TFA (22 μL,
0.290 mmol) dissolved in dry THF (0.5 mL) was added at 0 °C, and
the reaction mixture was warmed to 21 °C and stirred for 24.5 h.
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The reaction was quenched with an aqueous saturated NaHCO3
solution and diluted with EtOAc. The organic and aqueous phases
were separated, and the aqueous phase was extracted with EtOAc
(3 ×). The combined organic layers were washed with brine, dried
with Na2SO4, filtered and dried in vacuo. The crude product was
purified by column chromatography [heptane/EtOAc (1:1)→ EtOAc/
MeOH (10:1)]. The dried product was dissolved in CH2Cl2 (5 mL)
and washed with aqueous NH4OH (5 mL). The aqueous layer was
extracted with CH2Cl2 (3 × 5 mL), and the combined organic layers
were washed with brine, dried with Na2SO4, filtered and dried in
vacuo to afford 7Bc (27.5 mg, 0.051 mmol) as a purple solid. Yield
(BORSM): 74 %. RF = 0.32 (EtOAc/Et3N, 8:1). 1H NMR (400 MHz,
CDCl3): δ = 7.70 (br. s, 1 H), 7.62–7.55 (m, 4 H), 7.10 (d, J = 8.6 Hz,
1 H), 7.04 (d, J = 1.8 Hz, 1 H), 7.02 (dd, J = 8.2, 1.9 Hz, 1 H), 6.86 (d,
J = 2.4 Hz, 1 H), 6.83 (d, J = 8.2 Hz, 1 H), 6.68 (dd, J = 8.6, 2.4 Hz, 1
H), 4.53 (dd, J = 10.7, 3.0 Hz, 1 H), 4.41 (dd, J = 10.7, 3.0 Hz, 1 H),
3.90 (s, 3 H), 3.86 (s, 3 H), 3.34–3.16 (m, 2 H), 2.66 (t, J = 5.7 Hz, 2
H), 2.19–1.91 (m, 5 H) ppm. 13C NMR (101 MHz, CDCl3): δ = 149.6,
149.1, 148.5, 148.3, 140.3, 136.7, 130.9, 129.6 (q, J = 32.4 Hz), 128.2,
127.3 (2 ×), 125.6 (q, J = 3.7 Hz, 2 ×), 124.3 (q, J = 272.0 Hz, CF3),
119.1, 111.7, 111.5, 111.3, 110.2, 108.3, 103.5, 56.7, 56.6, 56.1, 56.0,
53.4, 44.5, 44.3, 39.3, 23.1 ppm. FTIR: ν˜ = 3364, 3305, 2931, 2836,
1591, 1509, 1223, 1140, 1024, 800 cm–1. HRMS (ESI): calcd. for
[C30H30F3N3O3 + H]+ 538.23216; found 538.23175 (|Δ| = 0.8 ppm).
(2S,4S,6R)-2-(3,4-Dimethoxyphenyl)-6-[4-(pentafluoro-λ6-
sulfanyl)phenyl]-2′,3′,4′,9′-tetrahydrospiro[piperidine-4,1′-pyr-
ido[3,4-b]indol]-6′-ol (7Cc): Et3N (19 μL, 0.137 mmol) dissolved in
dry THF (0.5 mL) and Ti(OiPr)4 (44 μL, 0.149 mmol) dissolved in dry
THF (0.5 mL) were added to a mixture of 4A (50 mg, 0.114 mmol)
and 5-hydroxytryptamine hydrochloride (29.2 mg, 0.137 mmol) in
dry THF (2 mL). After 6 h, TFA (19 μL, 0.251 mmol) dissolved in dry
THF (0.5 mL) was added at 0 °C, and the reaction mixture was
warmed to 21 °C and stirred for 20 h. The reaction was quenched
with NaHCO3 and the mixture diluted with EtOAc. The organic layer
was separated, and the aqueous phase was extracted with EtOAc
(4 ×). The combined organic layers were washed with brine, dried
with Na2SO4, filtered and dried in vacuo. The crude product was
purified by column chromatography [heptane/EtOAc (1:1)→ EtOAc/
MeOH (10:1)], and the dried product was dissolved in CH2Cl2 (5 mL)
and washed with aqueous NH4OH (5 mL). The aqueous phase was
extracted with CH2Cl2 (3 × 5 mL), and the combined organic layers
were washed with brine, dried with Na2SO4, filtered and dried in
vacuo to afford 7Cc (32.4 mg, 0.054 mmol) as a purple solid. Yield
(BORSM): 76 %. RF = 0.37 (EtOAc/Et3N, 8:1). 1H NMR (500 MHz,
CDCl3): δ = 7.81 (br. s, 1 H), 7.71–7.66 (m, 2 H), 7.59–7.54 (m, 2 H),
7.08 (d, J = 8.6 Hz, 1 H), 7.04 (d, J = 1.9 Hz, 1 H), 7.01 (dd, J = 8.2,
1.9 Hz, 1 H), 6.84 (d, J = 2.4 Hz, 1 H), 6.82 (d, J = 8.3 Hz, 1 H), 6.67
(dd, J = 8.6, 2.4 Hz, 1 H), 4.54–4.50 (m, 1 H), 4.41 (dd, J = 11.2,
2.2 Hz, 1 H), 3.87 (s, 3 H), 3.85 (s, 3 H), 3.29–3.16 (m, 2 H), 2.62 (t,
J = 5.6 Hz, 2 H), 2.13–1.90 (m, 5 H) ppm. 13C NMR (101 MHz, CDCl3):
δ = 153.0 (quint, J = 16.9 Hz), 149.6, 149.2, 148.5, 148.3, 140.2, 136.7,
130.9, 128.2, 127.2 (2 ×), 126.3 (quint, J = 4.2 Hz, 2 ×), 119.1, 111.7,
111.5, 111.3, 110.2, 108.4, 103.5, 56.5, 56.4, 56.1, 56.1, 53.3, 44.6,
44.3, 39.3, 23.1 ppm. FTIR: ν˜ = 3367, 2961, 2839, 1592, 1516, 1260,
103, 799 cm–1. HRMS (ESI): calcd. for [C29H30F5N3O3S + H]+
596.20116; found 596.20063 (|Δ| = 0.9 ppm).
General Procedure for the Synthesis of Compounds 7Ad–Cd: A
solution of Et3N (1.20 equiv.) in dry THF (0.5 mL) and a solution of
Ti(OiPr)4 (1.30 equiv.) in dry THF (0.5 mL) were added to a mixture
of piperidin-4-one 4A–C (1.00 equiv.) and 5-fluorotryptamine hydro-
chloride (1.20 equiv.) in dry THF (2 mL) at 21 °C under argon. After
4–7 h, TfOH (3.00 equiv. for 7Ad and 7Bd and 3.50 equiv. for 7Cd)
dissolved in dry THF (0.5 mL) was added at 0 °C, and the reaction
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mixture was warmed to 21 °C and stirred for 22–25 h. The reaction
was quenched with a saturated NaHCO3 solution and the mixture
diluted with EtOAc. The layers were separated, and the aqueous
phase was extracted with EtOAc (3 ×). The combined organic layers
were washed with brine, dried with Na2SO4, filtered and concen-
trated in vacuo. The crude product was purified by column chroma-
tography [heptane/EtOAc (2:1) → EtOAc/MeOH (10:1)], and the
dried product was dissolved in CH2Cl2 (5 mL) and washed with
aqueous NH4OH (5 mL). The aqueous phase was extracted with
CH2Cl2 (3 × 5 mL), and the combined organic layers were washed
with brine, dried with Na2SO4, filtered and dried in vacuo to afford
compounds 7Ad–Cd.
(2S,4S,6R)-2-(3,4-Dimethoxyphenyl)-6′-fluoro-6-(4-fluoro-
phenyl)-2′,3′,4′,9′-tetrahydrospiro[piperidine-4,1′-pyrido[3,4-b]-
indole] (7Ad): According to the general procedure, the reaction of
piperidin-4-one 4A (50 mg, 0.152 mmol) afforded 7Ad (46.1 mg,
0.094 mmol) as a yellow solid. Yield (BORSM): 74 %. RF = 0.37 (hept-
ane/EtOAc/Et3N, 4:4:1). 1H NMR (500 MHz, CDCl3): δ = 7.93 (br. s, 1
H), 7.50–7.43 (m, 2 H), 7.20–7.16 (m, 1 H), 7.10 (dd, J = 9.4, 2.5 Hz,
1 H), 7.04 (d, J = 2.0 Hz, 1 H), 7.02–6.98 (m, 3 H), 6.86 (td, J = 9.2,
2.5 Hz, 1 H), 6.82 (d, J = 8.2 Hz, 1 H), 4.46–4.43 (m, 1 H), 4.40 (dd,
J = 10.8, 3.1 Hz, 1 H), 3.91 (s, 3 H), 3.86 (s, 3 H), 3.25 (t, J = 5.8 Hz,
2 H), 2.69 (t, J = 5.8 Hz, 2 H), 2.09–1.93 (m, 4 H), 1.72 (br. s, 2 H)
ppm. 13C NMR (126 MHz, CDCl3): δ = 162.1 (d, J = 245.2 Hz), 157.9
(d, J = 234.3 Hz), 149.1, 148.4, 141.4, 140.4, 137.1, 132.1, 128.4 (d,
J = 7.9 Hz, 2 ×), 127.9 (d, J = 9.8 Hz), 119.0, 115.4 (d, J = 21.1 Hz,
2 ×), 111.4 (d, J = 9.4 Hz), 111.2, 110.1, 109.9 (d, J = 26.0 Hz), 109.1
(d, J = 4.3 Hz), 103.4 (d, J = 23.2 Hz), 56.6, 56.3, 56.1, 56.1, 53.3, 45.0,
45.0, 39.3, 23.2 ppm. FTIR: ν˜ = 3362, 2930, 2838, 1601, 1508, 1225,
1139, 1025, 798 cm–1. HRMS (ESI): calcd. for [C29H29F2N3O2 + H]+
490.23155; found 490.23061 (|Δ| = 0.9 ppm).
(2S,4S,6R)-2-(3,4-Dimethoxyphenyl)-6′-fluoro-6-[4-(trifluoro-
methyl)phenyl]-2′,3′,4′,9′-tetrahydrospiro[piperidine-4,1′-pyr-
ido[3,4-b]indole] (7Bd): According to the general procedure, the
reaction of piperidin-4-one 4B (50 mg, 0.132 mmol) afforded 7Bd
(21.9 mg, 0.041 mmol) as a yellow solid. In this case, after applying
the general procedure, the crude product was purified for a second
time by ion-exchange column chromatography (ISOLUTE SCX-2).
The dried product was dissolved in CH2Cl2 (5 mL) and washed with
aqueous NH4OH (5 mL). The aqueous phase was extracted with
CH2Cl2 (3 × 5 mL), and the combined organic layers were washed
with brine, dried with Na2SO4, filtered and dried in vacuo. Yield
(BORSM): 37 %. RF = 0.41 (heptane/EtOAc/Et3N, 4:4:1). 1H NMR
(500 MHz, CDCl3): δ = 7.94 (br. s, 1 H), 7.65–7.55 (m, 4 H), 7.20–7.15
(m, 1 H), 7.10 (dd, J = 9.4, 2.4 Hz, 1 H), 7.08–7.04 (m, 1 H), 7.06–7.00
(m, 1 H), 6.86 (td, J = 9.2, 2.6 Hz, 1 H), 6.83 (d, J = 8.3 Hz, 1 H), 4.57–
4.52 (m, 1 H), 4.45–4.41 (m, 1 H), 3.91 (s, 3 H), 3.86 (s, 3 H), 3.29–
3.22 (m, 2 H), 2.70 (t, J = 5.5 Hz, 2 H), 2.09–1.92 (m, 4 H), 1.80 (br.
s, 2 H) ppm. 13C NMR (101 MHz, CDCl3): δ = 157.9 (d, J = 234.3 Hz),
149.2, 148.5, 148.4, 141.1, 136.8, 132.1, 129.7 (q, J = 32.6 Hz), 127.9
(d, J = 9.6 Hz), 127.3 (2 ×), 125.6 (q, J = 3.4 Hz, 2 ×), 124.3 (q, J =
271.5 Hz, CF3), 119.0, 111.4 (d, J = 9.6 Hz), 111.3, 110.2, 110.0 (d, J =
26.0 Hz), 109.1 (d, J = 4.5 Hz), 103.4 (d, J = 23.2 Hz), 56.6, 56.5, 56.1,
56.1, 53.2, 44.6, 44.4, 39.3, 23.1 ppm. FTIR: ν˜ = 3362, 2935, 2837,
1586, 1514, 1261, 1017, 799 cm–1 . HRMS (ESI ) : ca lcd. for
[C30H29F4N3O2 + H]+ 540.22734; found 540.22741 (|Δ| = 0.1 ppm).
(2S,4S,6R)-2-(3,4-Dimethoxyphenyl)-6′-fluoro-6-[4-(penta-
fluoro-λ6-sulfanyl)phenyl]-2′,3′,4′,9′-tetrahydrospiro[piper-
idine-4,1′-pyrido[3,4-b]indole] (7Cd): According to the general
procedure, the reaction of piperidin-4-one 4C (50 mg, 0.114 mmol)
afforded 7Cd (27.6 mg, 0.046 mmol) as a yellow solid. Yield
(BORSM): 52 %. RF = 0.25 (heptane/EtOAc/Et3N, 4:4:1). 1H NMR
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(500 MHz, CDCl3): δ = 8.02 (br. s, 1 H), 7.71 (d, J = 8.8 Hz, 2 H), 7.58
(d, J = 8.4 Hz, 2 H), 7.20–7.15 (m, 1 H), 7.10 (dd, J = 9.5, 2.5 Hz, 1
H), 7.04 (d, J = 2.0 Hz, 1 H), 7.02 (dd, J = 8.2, 2.0 Hz, 1 H), 6.87 (td,
J = 9.1, 2.6 Hz, 1 H), 6.83 (d, J = 8.2 Hz, 1 H), 4.54 (dd, J = 7.6, 6.1 Hz,
1 H), 4.42 (dd, J = 11.0, 2.2 Hz, 1 H), 3.91 (s, 3 H), 3.86 (s, 3 H), 3.31–
3.20 (m, 2 H), 2.69 (t, J = 5.7 Hz, 2 H), 2.13–1.96 (m, 4 H) ppm. 13C
NMR (101 MHz, CDCl3): δ = 157.9 (d, J = 234.4 Hz), 153.0 (quint, J =
16.9 Hz), 149.2, 148.5, 148.4, 141.0, 136.8, 132.1, 127.9 (d, J = 9.6 Hz),
127.2 (2 ×), 126.3 (quint, J = 4.5 Hz, 2×), 119.0, 111.4 (d, J = 9.8 Hz),
111.3, 110.1, 110.0 (d, J = 26.6 Hz), 109.2 (d, J = 4.5 Hz), 103.4 (d,
J = 23.4 Hz), 56.4, 56.3, 56.1 (2 ×), 53.2, 44.9, 44.6, 39.3, 23.2 ppm.
FTIR: ν˜ = 3367, 2962, 2839, 1588, 1515, 1260, 1022, 795 cm–1. HRMS
(ESI): calcd. for [C29H29F6N3O2S + H]+ 598.19536; found 598.19629
(|Δ| = 1.6 ppm).
General Procedure for the Synthesis of Compounds 12 and 13:
Ti(OiPr)4 was added to a mixture of piperidin-4-one 4A (1.00 equiv.)
and the amine [1.20 equiv., 2-(1H-indol-2-yl)ethan-1-amine (9) for
12 and 2-(1H-pyrrol-2-yl)ethan-1-amine (11) for 13] in dry THF
(3 mL) at 21 °C under argon. After 6 h, TFA (2.20 equiv.) was added
at 0 °C, and the reaction mixture was warmed to 21 °C and stirred
overnight. The reaction was quenched with a saturated NaHCO3
solution (3 mL) and the mixture diluted with EtOAc. The layers were
separated, and the aqueous phase was extracted with EtOAc (4 ×
6 mL). The combined organic layers were washed with brine, dried
with Na2SO4, filtered and concentrated in vacuo. The crude product
was purified by column chromatography [heptane/EtOAc (2:1) →
EtOAc], and the dried product was dissolved in CH2Cl2 (5 mL) and
washed with aqueous NH4OH (5 mL). The aqueous phase was ex-
tracted with CH2Cl2 (3 × 5 mL), and the combined organic layers
were washed with brine, dried with Na2SO4, filtered and dried in
vacuo to afford compounds 12 and 13.
(2S,4S,6R)-2-(3,4-Dimethoxyphenyl)-6-(4-fluorophenyl)-
2′,3′,4′,5′-tetrahydrospiro[piperidine-4,1′-pyrido[4,3-b]indole]
(12): According to the general procedure, the reaction of piperidin-
4-one 4A (15 mg, 0.05 mmol) afforded 12 (12 mg, 0.03 mmol). Yield:
52 %. RF = 0.35 (EtOAc/Et3N, 8:1). 1H NMR (400 MHz, CDCl3): δ =
7.88–7.75 (m, 2 H), 7.51–7.47 (m, 2 H), 7.31–7.27 (m, 1 H), 7.14–7.09
(m, 2 H), 7.08–7.03 (m, 2 H), 7.03–6.95 (m, 2 H), 6.85–6.80 (m, 1 H),
4.47–4.41 (m, 1 H), 4.40 (dd, J = 12.2, 2.2 Hz, 1 H), 3.90 (s, 3 H), 3.85
(s, 3 H), 3.26 (t, J = 5.6 Hz, 2 H), 2.74 (t, J = 5.6 Hz, 2 H), 2.60–2.39
(m, 2 H), 1.92–1.82 (m, 2 H) ppm. 13C NMR (101 MHz, CDCl3): δ =
162.0 (indirect observation), 149.0, 148.2, 140.0 (indirect observa-
tion), 137.9 (indirect observation), 132.5, 131.1, 128.5 (d, J = 7.8 Hz,
2 ×), 125.1, 121.2, 119.5, 119.4, 119.0, 116.4, 115.2 (d, J = 21.1 Hz,
2 ×), 111.3, 110.9, 110.4, 56.9, 56.6, 56.1 (2×), 54.2, 44.8, 44.6, 38.7,
24.8 ppm. FTIR: ν˜ = 3366, 2957, 2856, 1602, 1508, 1229, 1156, 1026,
763 cm–1. HRMS (ESI): calcd. for [C29H31F1N3O2 + H]+ 472.24003;
found 472.24094 (|Δ| = 1.92 ppm).
(2S,4S,6R)-2-(3,4-Dimethoxyphenyl)-6-(4-fluorophenyl)-
1′,5′,6′,7′-tetrahydrospiro[piperidine-4,4′-pyrrolo[3,2-c]-
pyridine] (13): According to the general procedure, the reaction of
piperidin-4-one 4A (40 mg, 0.12 mmol) afforded 13 (22 mg,
0.062 mmol). Yield: 52 %. RF = 0.45 (EtOAc/Et3N, 8:1). 1H NMR
(400 MHz, CDCl3): δ = 7.79 (br. s, 1 H), 7.49–7.39 (m, 2 H), 7.06–6.95
(m, 4 H), 6.82 (d, J = 8.2 Hz, 1 H), 6.60 (t, J = 2.7 Hz, 1 H), 6.06 (t,
J = 2.7 Hz, 1 H), 4.33 (dd, J = 11.3, 3.5 Hz, 1 H), 4.29 (dd, J = 11.6,
2.9 Hz, 1 H), 3.90 (s, 3 H), 3.86 (s, 3 H), 3.20 (t, J = 5.8 Hz, 2 H), 2.58
(t, J = 5.8 Hz, 2 H), 2.07–1.79 (m, 4 H), 1.68 (br. s, 1 H) ppm. 13C
NMR (101 MHz, CDCl3): δ = 162.0 (d, J = 244.4 Hz), 149.0, 148.1,
141.1 (d, J = 3.0 Hz), 138.0, 128.4 (d, J = 7.9 Hz, 2 ×), 124.8, 118.9,
116.0, 115.1 (d, J = 21.1 Hz, 2 ×), 111.2, 110.9, 110.2, 104.5, 56.8,
56.5, 56.1 (2×), 53.5, 46.4, 46.3, 38.9, 24.3 ppm. FTIR: ν˜ = 3379, 2930,
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2836, 1604, 1508, 1227, 1156, 1026, 765 cm–1. HRMS (ESI): calcd. for
[C25H29F1N3O2 + H]+ 422.22438; found 422.22591 (|Δ| = 3.63 ppm).
Supporting Information (see footnote on the first page of this
article): Full experimental details for the preparation of the com-
pounds described herein, characterization of new compounds and
1H and 13C NMR spectra.
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